Imaging of Cholangiocarcinoma
Executive Summary
Cholangiocarcinoma (CC) is a highly aggressive malignancy of the biliary tract and represents the second most common primary hepatobiliary tumor. Its incidence is steadily increasing, particularly in Western countries. Because surgical resection remains the only potentially curative treatment—offering a five-year survival rate of 30–35%—accurate early diagnosis and precise staging are critical.
Imaging plays a central role in the management of CC, though the heterogeneous nature of the tumor presents significant diagnostic challenges. Computed Tomography (CT) is the standard modality for assessing surgical resectability and vascular infiltration, while Magnetic Resonance Imaging (MRI) combined with Magnetic Resonance Cholangiopancreatography (MRCP) is considered the modality of choice for biliary tract visualization and primary diagnosis. Positron Emission Tomography/Computed Tomography (PET/CT) has emerged as a superior tool for detecting lymph node involvement, distant metastasis, and disease recurrence.
Overview and Epidemiology
Cholangiocarcinoma accounts for 10–20% of all primary liver tumors. Approximately 95% of these cases are adenocarcinomas characterized by a high proportion of fibrous stroma.
Incidence and Risk Factors
Geographic Variation: The highest prevalence is found in Southeast Asia. In the US, incidence rates vary between 0.72 and 0.88 per 100,000.
Identified Risk Factors: Primary sclerosing cholangitis (PSC), liver fluke infestations (Opisthorchis viverrini, Clonorchis sinensis), hepatolithiasis, Thorotrast exposure, and choledochal cysts.
Anatomical and Morphological Classification
Tumors are categorized based on their location within the bile duct segments:
Intrahepatic (iCC): Divided into peripheral (6–8%) and perihilar (50–67%). Perihilar CC is also known as a Klatskin tumor.
Extrahepatic (eCC): Accounts for 27–42% of cases.
According to the Liver Cancer Study Group of Japan, iCC is further classified by growth pattern:
Mass-forming: The most common type.
Periductal infiltrating: Characterized by growth along the bile duct.
Intraductal growth: Characterized by irregular duct calibre and focal ectasia.
Primary Imaging Modalities
Ultrasound (US)
Transabdominal ultrasound is typically the initial diagnostic step when clinical findings suggest CC. It is effective for identifying bile duct obstruction and characterizing liver lesions. Recent advances, such as contrast-enhanced ultrasound (CEUS) and endosonography, show potential for better luminal and extraluminal mass evaluation.
Computed Tomography (CT)
CT is utilized in approximately 90% of suspected cases to assess tumor extension and resectability.
Scanning Protocols: Multiphase scanning is essential.
Pre-contrast: Detects intraductal stones.
Arterial Phase: Displays arterial anatomy for surgical planning.
Portal Venous Phase: Highlights incomplete rim-like enhancement and allows for precise tumor size estimation.
Late-phase (5–10 min): Shows delayed enhancement representing fibrous stroma.
Surgical Planning: CT volumetry is used preoperatively to estimate potential liver remnants and avoid postoperative small-for-size syndrome.
Magnetic Resonance Imaging (MRI) and MRCP
MRI is the preferred modality for diagnosis due to its superior tissue contrast.
MRCP: The most accurate non-invasive technique for biliary assessment. It uses heavily T2-weighted sequences to create high fluid signal in the ducts, allowing for the detection of small masses and strictures.
Contrast Enhancement: Mass-forming iCC typically appears T1 hypointense and T2 hyperintense. When using hepatocyte-specific contrast agents, these tumors often exhibit a "cloud-like" appearance with a hyperintense center.
PET/CT (18F-FDG)
PET/CT provides metabolic data that complements anatomical imaging.
Sensitivity: High for iCC (95%) but lower for pCC (84%) and eCC (76%).
Limitations: It is less effective for tumors smaller than 1 cm, infiltrative growth, or tumors with high mucin content. False positives can occur due to inflammation from stents or chemotherapy.
Staging and Prognosis
Primary Staging Accuracy
The effectiveness of imaging varies depending on the staging requirement:
Prognostic Indicators
Enhancement Patterns: In mass-forming iCC, intratumoural enhancement greater than two-thirds on delayed CT scans is associated with a worse prognosis.
Vascularity: Augmented arterial enhancement correlates with higher cellularity, less fibrotic tissue, and higher survival rates.
Metabolic Activity: High metabolic activity on PET/CT (SUVmean > 8.5) may predict lower disease-free survival.
Recurrence and Monitoring
Tumor recurrence is highly prevalent, occurring in 60–80% of patients within five years of resection.
Recurrence Patterns: 53.5% of patients develop recurrence. Common sites include the liver (60.9%), lungs (24%), peritoneum (18%), and bones (14%).
Detection: While CT and MRI are standard for follow-up, PET/CT is significantly more sensitive (94% vs 82% for CT) and specific (100% vs 43% for CT) in detecting recurrence, particularly when tumor markers are elevated but conventional imaging is negative. It is also effective at differentiating post-therapeutic fibrosis from active tumor recurrence.
Innovative and Emerging Techniques
Recent technological advancements are refining the diagnostic capabilities of CT:
Dual-Energy CT (DECT): Allows for the calculation of virtual non-enhanced images to detect stones without extra scans. Iodine mapping improves the detection of vascularity and thrombosis.
Volume Perfusion CT (VPCT): Assesses exact vascularization. CC typically shows increased hepatic arterial perfusion and decreased portal perfusion. This is particularly useful for monitoring response to anti-angiogenetic or targeted therapies where tumor size may not change immediately.
Low-keV Monoenergetic Reconstructions: Improves the conspicuity of hypervascular liver tumors and helps differentiate benign from malignant lesions.
